Ionis Pharmaceuticals and Otsuka said their amyotrophic lateral sclerosis therapy met its primary endpoint in a Phase 3 study, setting up talks with regulators regarding potential expedited approvals. The update reinforces how antisense and RNA-targeted approaches continue to target late-stage disease-modifying goals with clinically measurable progression endpoints. The milestone also highlights the growing role of partnerships in managing global regulatory pathways and late-stage execution, particularly in rare neuromuscular diseases where timelines and data adequacy drive investment confidence.